Disruption of the AMPK–TBC1D1 nexus increases lipogenic gene expression and causes obesity in mice via promoting IGF1 secretion

Liang Chen, Qiaoli Chen, Bingxian Xie, Chao Quan, Sheng Yang, Sangsang Zhu, Ping Rong, Shuilian Zhou, Kei Sakamoto, Carol MacKintosh, Hong Yu Wang, Shuai ChenProceedings of the National Academy of Sciences 2016 · DOI

TL;DR

This study reveals a novel signaling pathway where the energy sensor AMPK, through its phosphorylation of TBC1D1, regulates IGF1 secretion. Disrupting this link leads to increased IGF1, activating the PKB-mTOR pathway, promoting lipogenesis, and ultimately causing obesity in mice. This work uncovers a critical mechanism connecting energy status to metabolic health and offers potential therapeutic targets for obesity.

What Problem Does This Paper Address?

Obesity and related metabolic disorders like type 2 diabetes and non-alcoholic fatty liver disease are global health crises. While the energy-sensing kinase AMPK and the growth-promoting hormone IGF1 are known players in metabolism, the precise molecular links between them, especially in the context of energy status and lipogenesis (fat production), remain unclear. Specifically, TBC1D1, a protein known to be phosphorylated by AMPK, had an unknown in vivo role for this modification. This paper aims to elucidate the physiological significance of AMPK-mediated TBC1D1 phosphorylation and its contribution to metabolic regulation, particularly in the development of obesity.

Methods

The researchers employed a multi-pronged approach:

  • Genetically Modified Mice: They created a "knockin" mouse model where a key phosphorylation site (Ser231) on TBC1D1 was mutated to alanine (TBC1D1Ser231Ala). This mutation prevents AMPK from phosphorylating TBC1D1 at this specific site, allowing the study of its functional consequences.
  • Metabolic Phenotyping: The knockin mice were subjected to detailed physiological assessments, including body composition analysis (lean and fat mass), glucose and insulin tolerance tests, blood chemistry analysis (glucose, insulin, lipids), and histological examination of tissues like adipose and liver.
  • Molecular Biology Techniques:
    • Western Blotting: Used extensively to measure protein expression levels and phosphorylation status of key signaling molecules (e.g., AMPK, TBC1D1, PKB, mTOR, FASN, IGF1).
  • Immunoprecipitation: Employed to isolate specific proteins (like TBC1D1) and study their interactions with other molecules (e.g., 14-3-3 proteins).
  • Cell Culture: Primary hepatocytes, chondrocytes, adipocytes, and skeletal muscle cells were isolated from mice and cultured to study IGF1 secretion and signaling pathways in a controlled environment.
  • siRNA Knockdown: Used to specifically reduce the expression of genes like TBC1D1 and Rab8a to assess their roles in IGF1 secretion.
  • Immunofluorescence Microscopy: Utilized to visualize the co-localization of proteins (e.g., TBC1D1 and IGF1, Rab8a and IGF1) within cells.
  • QPCR: Used to measure mRNA expression levels of specific genes.
  • GTPase Activity Assays: Employed to assess the activity of Rab8a, a protein implicated in vesicle transport.

Datasets

Not discussed in the paper. The study relies on experimental data generated from mouse models and cell cultures.

Key Insights and Ideas

  • AMPK-TBC1D1-IGF1 Axis: The study establishes a critical signaling axis where AMPK's phosphorylation of TBC1D1 acts as a gatekeeper for IGF1 secretion. This is a novel finding that connects cellular energy status directly to systemic growth factor signaling.
  • TBC1D1's Role in IGF1 Vesicle Trafficking: TBC1D1 appears to be localized on IGF1 storage vesicles, and its phosphorylation by AMPK is crucial for regulating the release of IGF1. This suggests a direct role for TBC1D1 in the secretory pathway of IGF1.
  • IGF1 as a Mediator of Obesity: The research strongly implicates hypersecreted IGF1 as the direct driver of increased lipogenesis and subsequent obesity in the TBC1D1 mutant mice. This highlights IGF1's broader role beyond just growth promotion.
  • PKB-mTOR Pathway Activation: The increased IGF1 in the knockin mice robustly activates the PKB-mTOR pathway, a known regulator of cell growth and metabolism, leading to enhanced lipogenic gene expression.
  • Rab8a as a Key Effector: The study identifies Rab8a as a crucial downstream effector of TBC1D1 in regulating IGF1 secretion, specifically highlighting the importance of its GDP-bound form.

Key Results

  • Obesity in TBC1D1Ser231Ala Mice: Mice with the mutated TBC1D1 phosphorylation site developed obesity on a normal chow diet, exhibiting increased lean and fat mass as they aged.
  • Metabolic Syndrome Development: These mice also developed hyperglycemia, hyperinsulinemia, hypercholesterolemia, glucose intolerance, insulin resistance, and hepatic steatosis with age.
  • Elevated Plasma IGF1: TBC1D1Ser231Ala knockin mice showed significantly higher levels of IGF1 in their plasma.
  • Increased IGF1 Secretion: Primary hepatocytes, chondrocytes, adipocytes, and skeletal muscle from these mice exhibited increased IGF1 secretion rates.
  • PKB-mTOR Pathway Hyperactivation: The PKB-TSC2-mTOR pathway was constitutively activated in adipose tissue, skeletal muscle, and liver of the knockin mice.
  • Upregulation of Lipogenic Genes: The expression of fatty acid synthase (FASN), a key lipogenic enzyme, was significantly upregulated in the adipose tissue of the knockin mice.
  • Rab8a Knockdown Reverses IGF1 Hypersecretion: Knocking down Rab8a in primary hepatocytes from the knockin mice normalized IGF1 secretion.

Limitations and Future Work

  • Other Phosphorylation Sites: The study focuses on Ser231, but TBC1D1 has other phosphorylation sites. The authors acknowledge that these other sites might play roles in different cellular processes, such as contraction-stimulated glucose uptake in skeletal muscle, which was not supported by this study's findings for Ser231.
  • Upstream Regulators of AMPK: While the study shows AMPK's role, the specific upstream regulators of AMPK that control IGF1 secretion under energy-deficient conditions remain to be fully elucidated.
  • Mechanism of Rab8a Regulation: The precise mechanism by which GDP-bound Rab8a regulates IGF1 secretion requires further investigation, including the identification of its downstream effectors.
  • Therapeutic Potential: The findings suggest that targeting the AMPK-TBC1D1-IGF1 axis could be a strategy for combating obesity. The study also hints at the potential role of metformin in modulating IGF1 secretion, opening avenues for further research into its therapeutic mechanisms.

Summary updated

Abstract

Tre-2/USP6, BUB2, cdc16 domain family member 1 (the TBC domain is the GTPase activating protein domain) (TBC1D1) is a Rab GTPase activating protein that is phosphorylated on Ser(231) by the AMP-activated protein kinase (AMPK) in response to intracellular energy stress. However, the in vivo role and importance of this phosphorylation event remains unknown. To address this question, we generated a mouse model harboring a TBC1D1(Ser231Ala) knockin (KI) mutation and found that the KI mice developed obesity on a normal chow diet. Mechanistically, TBC1D1 is located on insulin-like growth factor 1 (IGF1) storage vesicles, and the KI mutation increases endocrinal and paracrinal/autocrinal IGF1 secretion in an Rab8a-dependent manner. Hypersecretion of IGF1 causes increased expression of lipogenic genes via activating the protein kinase B (PKB; also known as Akt)-mammalian target of rapamycin (mTOR) pathway in adipose tissues, which contributes to the development of obesity, diabetes, and hepatic steatosis as the KI mice age. Collectively, these findings demonstrate that the AMPK-TBC1D1 signaling nexus interacts with the PKB-mTOR pathway via IGF1 secretion, which consequently controls expression of lipogenic genes in the adipose tissue. These findings also have implications for drug discovery to combat obesity.
BibTeX
@inproceedings{chen2016disruption,
  author = {Liang Chen and Qiaoli Chen and Bingxian Xie and Chao Quan and Sheng Yang and Sangsang Zhu and Ping Rong and Shuilian Zhou and Kei Sakamoto and Carol MacKintosh and Hong Yu Wang and Shuai Chen},
  title = {{Disruption of the AMPK–TBC1D1 nexus increases lipogenic gene expression and causes obesity in mice via promoting IGF1 secretion}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2016},
  doi = {10.1073/pnas.1600581113},
}
Figure